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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
Primary objective
To assess the effectiveness of supportive interventions at improving the well-being of caregivers of people with a brain or spinal cord
tumour.
Secondary objectives
1. To assess the effects of supportive interventions for caregivers in improving the physical and emotional well-being of patients
with a brain or spinal cord tumour
2. To assess the health economic benefits of supportive interventions for caregivers
B A C K G R O U N D
Description of the condition
The diagnosis and treatment of a brain or spinal cord tumour
can have a huge impact on the lives of patients and their families.
Approximately 28 per 100,000 adults aged 20 and over are affected
by central nervous system tumours, with the majority of tumours
(approximately 66%) being non-malignant (Ostrom 2014). In
children and young adults under 19 years of age, central nervous
system tumours are the most common tumour, with an annual
age-adjusted incidence rate of 5.4 per 100,000 (Ostrom 2014).
The treatment and expected outcome depend heavily on the tu-
mour type, molecular markers, tumour grade, and location. Treat-
ment generally consists of surgical intervention, radiotherapy, che-
motherapy, or a combination of these treatment methods. Inmak-
ing treatment decisions, any benefit from treatment is weighed
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against the expected quality of life (QoL) and symptom burden of
patients.
Depending upon the tumour location and treatment side effects,
patients can experience neurological symptoms such as weakness,
sensory loss, and motor dysfunction, or visual-perceptual deficits
and problems with speech and language (Mukand 2001). Cog-
nitive deficits such as problems with memory and concentration
occur in the majority of patients, and epilepsy is also common
(Armstrong 2016; Durand 2015; van Loon 2015). Moreover, fa-
tigue, depression and changes in personality and behaviour are fre-
quently reported throughout the course of the disease (Armstrong
2016b; Cavers 2012; Rooney 2011). These symptoms can influ-
ence the degree to which patients can participate in vocational
and social activities and can even prevent independence and affect
QoL (Aaronson 2011; Klein 2001; Macartney 2014).
Patients commonly come to rely on their family caregivers (e.g.
spouses, family members, or close friends) for both physical and
emotional support. Consequently, many family caregivers expe-
rience considerable burden and distress, and consistently report
feeling ill-prepared for their caregiving role (Choi 2012; Sterckx
2013). Therefore interventions to support caregivers are expected
to help the caregiver, the patient and family unit.
Various studies have explored the needs of family caregivers in
neuro-oncology, and show a need for clear information and
communication with healthcare professionals: around symptoms,
treatment, and available resources; health service needs and care
coordination; and the need for psychological and social supportive
care options (Moore 2013; Sterckx 2013).
Description of the intervention
Individual caregivers’ needs can vary greatly depending on the
time point in treatment, the person’s social support system, ex-
pectations and experienced burden (i.e. the stress experienced as
a result of the home care situation) (Ownsworth 2015). There-
fore, any intervention programme aimed at improving the well-
being of family caregivers in neuro-oncology will be considered
for this review. Here, the term ’well-being’ encompasses all aspects
of QoL, psychological distress, coping and mastery, i.e. the feeling
of being in control of the caregiving situation.
The interventions under investigation may include, but are not
limited to, programmes aimed at empowering family caregivers
through:
1. improving information provision; e.g. what to expect from
their role as a family caregiver; teaching caregivers what the
treatment options are; educating them on supportive care
options;
2. caregiver skills training; e.g. how to recognise (changes in)
patients’ symptoms; how to manage symptoms or improve
patients’ everyday functioning; and
3. psychosocial support; e.g. psychosocial interventions to
help caregivers cope better; therapeutic interventions to promote
a healthy relationship between the patient and caregiver;
bereavement support after the patient has passed.
It is not expected that effectiveness of interventionswill varywithin
different subgroups of caregivers, e.g. grade of tumour, age of pa-
tient. The interventions are not expected to pose a risk to care-
givers, however, length or complexity of intervention programmes
may increase caregiver burden and could cause caregivers to feel
overwhelmed instead of supported.
How the intervention might work
Supportive interventions for family caregivers in neuro-oncology
may help in various ways.
Improving information provision and caregiver skills training may
help prepare family members and friends for their caregiving role
and activities. When caregivers learn more about the disease and
its symptoms, they feel more confident in distinguishing between
which (changes in) symptoms could be normal or expected and
which may require medical follow-up. Through this mechanism,
patient outcomes may be improved as better symptom manage-
ment may be initiated sooner and new tumour activity may be de-
tected earlier in the disease trajectory, allowing treatment to com-
mence.Moreover, symptomsmay be recognised and treated before
becoming more serious and requiring inpatient treatment, thus
potentially reducing healthcare costs. Finally, increasing caregivers’
confidence in dealing with these medical issues can substantially
improve their feelings of mastery. This may have a positive effect
on their overall well-being, their QoL, and the quality of care they
deliver in the home situation.
Psychosocial support may provide caregivers with the tools to im-
prove coping strategies to deal with the psychological burden of
being a caregiver to a person who has been diagnosed with a brain
or spinal cord tumour. Many patients and caregivers struggle with
maintaining a healthy relationship after changes in the patient’s
personality and behaviour, and psychological support to caregivers
or patient-caregiver dyads can help couples work through these
issues together. It is known that patients who go through divorce
or separation are more likely to be hospitalised and less likely to
complete treatment, become involved in clinical trials, or die at
home (Glantz 2009). Promoting healthy patient-caregiver rela-
tionships may therefore also have a positive effect on long-term
patient outcomes. This can help decrease caregivers’ levels of dis-
tress and burden. As many caregivers will provide care for a longer
period of time, up to many years on end, decreasing distress and
burden may prove beneficial as the physical consequences of long-
term high levels of stress may be prevented. Finally, maintaining
good physical as well as emotional health in caregivers will allow
them to continue their caregiving tasks, which will benefit patients
as well.
2Interventions to help support caregivers of people with a brain or spinal cord tumour (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Why it is important to do this review
Meeting the needs of family caregivers in neuro-oncology, by de-
creasing their distress and burden and improving their sense of
mastery, is imperative in order to maintain their emotional and
physical health. Protecting caregivers’ QoL can enable them to
continue their caregiving activities to maintain the best possible
level of patients’ well-being. Indeed, caregiver support is listed as
a top research priority in neuro-oncology in the UK through the
James Lind Alliance Neuro-Oncology Partnership (Grant 2015).
Furthermore, the NHS has made a number of commitments
to caregivers, including supporting caregivers’ mental health and
well-being alongside physical needs (NHS England 2014).
Information and support for caregivers of patients with brain and
spinal cord tumours is becoming more widely available and care-
giver programmes are becoming more common in clinical practice
in some centres. However, large-scale implementation of caregiver
support may be hindered by the lack of high-quality evidence for
the effects of caregiver interventions in populations of brain and
spinal tumour patients. Indeed, a recent report from Macmillan
Cancer Support reveals that more than half of family caregivers in
oncology do not receive support at present (Macmillan/You Gov
2016). This systematic review will provide an overview of care-
giver interventions for those taking care of patients with a brain or
spinal tumour, assessed in randomised controlled trials (RCTs). It
will also provide a brief economic summary of the health economic
benefits where these have been measured. It is expected that this
will be useful to make recommendations for policy and practice.
O B J E C T I V E S
Primary objective
To assess the effectiveness of supportive interventions at improving
the well-being of caregivers of people with a brain or spinal cord
tumour.
Secondary objectives
1. To assess the effects of supportive interventions for
caregivers in improving the physical and emotional well-being of
patients with a brain or spinal cord tumour
2. To assess the health economic benefits of supportive
interventions for caregivers
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and quasi-RCTs. Trials in
which quasi-randomisedmethods are usedwill be included if there
is sufficient evidence that the treatment and control groups are
similar at baseline. If this is unclear, trial authors will be contacted
to provide clarification.
Types of participants
We will include studies with adult caregivers (18 years or older)
for people with a brain or spinal cord tumour. The people they
provide care for can be of any age, suffering from any type of
malignant or benign, primary or secondary brain or spinal cord
tumour, at any time during the disease trajectory.
Types of interventions
Any type of intervention whose primary aim is to improve care-
giver well-being will be considered. We will include trials which
evaluate the effectiveness of individual and group-based interven-
tions for caregivers, or for patient-caregiver dyads as long as care-
giver outcomes are reported on. No restrictions will be placed on:
the setting, e.g. in the hospital, clinic, psychologist office, at home
or elsewhere; the facilitator of the intervention, e.g. a healthcare
professional, social worker, or (guided) self-help; or the method
of delivery of the intervention, e.g. delivered face-to-face, online,
written, or by telephone. Any control condition is acceptable, e.g.
wait list control groups, attention-only control groups, informa-
tion-only control groups. Trial authors will be contacted if it is
unclear whether a trial meets our inclusion criteria.
Types of outcome measures
For all primary outcomes we will accept recognised caregiver ques-
tionnaires or instrumentsmeasuringmood, caregiver burden,mas-
tery, marital adjustment, quality of life and physical functioning.
Where measured, the effect on patient emotional and physical
well-being patient questionnaires will be assessed under Secondary
outcomes. Acceptable outcomes are detailed below.
Primary outcomes
Outcomes related to caregiver emotional or physical well-
being
1. Psychological distress (depression and anxiety), e.g.
Hospital Anxiety and Depression Scale (HADS; Crawford
2001), Center for Epidemiological Studies Depression Scale
(CES-D; Radloff 1977)
2. Caregiver burden, e.g. Caregiver Reaction Assessment
(CRA; Given 1992)
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3. Caregiver mastery, e.g. Mastery Scale (Pearlin 1978)
4. Quality of patient-caregiver relationship, e.g. Locke-
Wallace Short Marital Adjustment Test for spousal relationships
(Jiang 2013)
5. Quality of life (QoL), either caregiver specific, e.g.
Caregiver QoL index-cancer (CQOLC; Weitzner 1999),
Caregiver oncology QoL questionnaire (CarGOQoL; Minaya
2012), or generic, e.g. Short Form Health Survey (SF-36;
McHorney 1993), EuroQol (EQ-5D Brooks 1996)
6. Physical functioning, e.g. number of chronic conditions
present, physical measures of stress levels (cytokines), physical
subscales of QoL questionnaires
Secondary outcomes
Outcomes related to patient emotional or physical well-being
1. Psychological distress (depression and anxiety), e.g.
Hospital Anxiety and Depression Scale (HADS; Crawford
2001), Center for Epidemiological Studies Depression Scale
(CES-D; Radloff 1977)
2. Quality of life, e.g. European Organization for Research
and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30;
Aaronson 1993); Functional Assessment of Cancer Therapy
(FACT; Weitzner 1995), Short Form Health Survey (SF-36;
McHorney 1993)
3. Symptom management, number and/or severity of
symptoms measured with e.g. MD Anderson Symptom
Inventory-Brain Tumor Module (MDASI-BT; Armstrong 2006),
EORTC Brain Cancer Module (EORTC QLQ-BN20;
Taphoorn 2010)
4. Number of visits to the emergency room, e.g. as detailed in
medical records
5. Number and length of hospitalisations, e.g. as detailed in
medical records
Outcomes related to the health economic effects
1. Caregiver and/or patient employment status, e.g. self-
reported
2. Productivity loss at work of caregiver and/or patient, e.g.
self-reported
3. Caregiver healthcare utilisation for acute and/or chronic
conditions, e.g. self-reported or as detailed in caregiver’s medical
records
Wewill not exclude trials with different outcomes than thosemen-
tioned above, if they measure the same construct.
Search methods for identification of studies
No restrictions will be made based on type of publication, year of
publication, or language. Papers published in languages other than
English, Dutch or German will be translated. Both published and
unpublished RCTs will be considered.
Electronic searches
We will search: the Cochrane Central Register of Controlled Tri-
als (CENTRAL; latest issue), MEDLINE (1964 to date), Embase
(1980 to date), and ClinicalTrials.gov (clinicaltrials.gov/). The
MEDLINE search strategy is detailed in Appendix 1.
Searching other resources
The references of identified studieswill be handsearched for studies
that were not identified through the electronic search.
Conference abstracts and proceedings from the last five years
will be searched through the American Society of Clinical On-
cology (ASCO; www.asco.org/ASCO/Meetings), the Society for
Neuro-Oncology (SNO; supplements of Neuro-Oncology; neuro-
oncology.oxfordjournals.org/conent/by/year), and the Interna-
tional Psycho-Oncology Society (IPOS; special issues of Psycho-
Oncology;
The two main journals in the field of neuro-oncology, Neuro-
Oncology and Journal of Neuro-Oncology will be handsearched for
publications from the last year that were not identified through
the electronic search.
We will contact the authors of publications known to focus on
improving the well-being of caregivers of patients with a brain
or spinal cord tumour, to enquire about unpublished or ongoing
trials.
Data collection and analysis
Selection of studies
Two review authors will select studies for inclusion in this
Cochrane review. All titles and abstract will be screened by the
review authors independently. Discarded studies will be stored in
a file as potentially relevant. The eligible studies will be subject to
further independent assessment after full-text reports have been
retrieved. Disagreements between review authors will be resolved
by discussion and if disagreements persist, a third review author
will be asked for their opinion. If the published report contains too
little information to assess whether the trial should be included,
we will contact the study authors for further details. EndNote will
be used for database management.
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Data extraction and management
Two review authors will examine each selected report and ex-
tract data using a piloted data collection form based on Cochrane
Consumers andCommunication’sGroup data extraction template
(Cochrane CCG 2016). This data collection form will include
participant characteristics (e.g. age, sex, group size, patients’ tu-
mour type, grade, disease stage, etc) and information about the
supportive intervention, e.g. the method and duration, the time-
points at which the outcomes were assessed, the results (continu-
ous outcomes: mean difference and standard error; dichotomous
outcome data: number of caregivers who show an improvement
in terms of emotional or physical well-being as a proportion of the
total number treated) and information on adherence and attrition
(Chandler 2013).
If possible, we will assess the extent to which the following con-
founding factors may have influenced the results and the extent
to which these were controlled for in the analysis: caregiver edu-
cation, caregiver age, caregiver sex, caregiver income or socioeco-
nomic status, caregiver use of psychotropic medication, nature of
the relationship with the patient, patient diagnosis, patient age,
patient sex. We will contact trial authors if these data are not re-
ported on. Extracted data will be entered into Review Manager.
Again, the two authors mentioned above will discuss and any un-
certainties will be resolved by a third review author.
Assessment of risk of bias in included studies
The two review authors responsible for the selection of studies and
data extraction will also assess the risk of bias in accordance with
the Cochrane tool for assessing the risk of bias (Higgins 2011).
This includes several domains: random sequence generation; allo-
cation concealment; blinding of participants and personnel; blind-
ing of outcome assessment; incomplete outcome data; selective
reporting; other sources of bias. The risk of bias will be categorised
as high, low, or unclear. The assessments will be presented in a
’Risk of bias’ table. The risk of bias in the included studies will be
discussed and persisting disagreements between the review authors
will be resolved by a third review author. The risk of bias will be
incorporated in the interpretation of possible meta-analysis.
Measures of treatment effect
For dichotomous outcome data, we will present the number of
caregivers who show an improvement in terms of emotional or
physical well-being as a proportion of the total number treated.We
will calculate and present risk ratios (RRs) with 95% confidence
intervals (CIs).
For continuous outcome data from studies using the same instru-
ment, wewill estimatemean differences (MDs) between treatment
groups.Where different instruments are used, we will calculate the
standardised mean difference (SMD) by dividing the mean dif-
ference in post-intervention scores between the intervention and
control groups by the standard deviation of the outcome among
participants. We will present both the MD and SMD with 95%
CIs for individual outcomes in individual studies. If these data
are unavailable, we will present the reported significance levels in-
stead.
Unit of analysis issues
Different levels of randomisation (e.g. at the level of participants
or groups) will be taken into account. When there are long-term
follow-up assessments available within trials, we will analyse out-
comes for two different follow-up categories: short term, i.e. 0 to
3 months; or medium to long term, i.e. 4 months and more. If
studies with multiple intervention groups are identified, we will
make pair-wise comparisons between all possible pairs of inter-
vention groups. We will make sure that we do not double-count
participants in the analysis.
Dealing with missing data
The corresponding authors of the trials will be contacted inwriting
(email, post, or both) to obtain missing data. We will evaluate
the reporting of important numerical data such as the number of
screened and randomised participants, and whether intention-to-
treat or per-protocol analyses were done. Missing data will not be
imputed (Higgins 2011).
Assessment of heterogeneity
The impact of the heterogeneity of included intervention studies
will be assessed with the I2 statistic for each outcome. Substantial
heterogeneity will be defined as I2 > 50% and forest plots will be
visually inspected for heterogeneity. A certain degree of hetero-
geneity is expected, therefore a random-effects model will be used
for possible meta-analysis.
Assessment of reporting biases
If at least 10 studies are included, we will draw funnel plots of
treatment effect versus precision with the data from all studies
(Higgins 2011). The funnel plots will be visually inspected to
assess whether there has been selective reporting of outcomes.
Data synthesis
If trials include different outcomes, we will pool outcomes that
measure the same construct, or systematically report on outcomes
that do not measure the same construct.
We will perform a meta-analysis if we find two or more RCTs with
a low risk of bias in which study population, intervention and
outcome measures are comparable. We will create a ’Summary of
findings’ table following the Cochrane template (see Appendix 2).
This will include the primary and secondary outcomes as listed
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above. For each outcomewewill report the number of participants,
the overall quality of the evidence according to the GRADE levels
of evidence, and the effect size.
If a meta-analysis is not possible we will synthesise the findings
of the included studies in a table, following the GRADE levels of
evidence (Higgins 2011). The individual effect sizes of the studies
and 95% CI will be reported.
Review Manager will be used for the analyses (tech.cochrane.org/
revman).
Subgroup analysis and investigation of heterogeneity
If sufficient studies can be identified, i.e. at least two for each
subgroup, we will perform subgroup analyses for the study design
(RCT or quasi-RCT), the type of intervention, the type of control
group, timing (e.g. shortly after the patient’s diagnosis, during
initial anti-tumour treatment, following initial treatment, in the
palliative phase or during the bereavement phase), and patient
tumour type.
Sensitivity analysis
If sufficient data are available, we will perform a sensitivity analysis
to assess the robustness of results, e.g. excluding studies with high
risk of bias.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. exp Central Nervous System Neoplasms/
2. ((brain or cereb* or spinal cord or CNS or central nervous system) adj5 (cancer* or carcinoma* or tumor* or tumour* or malignan*
or neoplas* or lymphoma* or hemangioma*)).mp.
3. exp Glioma/
4. (glioma* or astrocytoma* or meningioma* or oligodendroglioma* or glioblastoma* or ependymoma* or medulloblastoma* or
craniopharyngioma* or pineal or pituitary or PNET* or DNET* or schwannoma*).mp.
5. 1 or 2 or 3 or 4
6. Caregivers/
7. exp Family/
8. (caregiver* or care giver* or carer*).mp.
9. ((family or families or spouse* or partner* or parent* or grandparent* or sibling* or relative* or friend* or husband* or wife or wives
or close person* or significant other* or child or children) and (care or caring)).mp.
10. 6 or 7 or 8 or 9
11. 5 and 10
12. randomized controlled trial.pt.
13. controlled clinical trial.pt.
14. randomized.ab.
15. placebo.ab.
16. clinical trials as topic.sh.
17. randomly.ab.
18. trial.ti.
19. 12 or 13 or 14 or 15 or 16 or 17 or 18
20. 11 and 19
Key:
mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier, pt=publication type,ab=abstract, ti=title, sh=subject heading
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Appendix 2. Example ’Summary of Findings’ table
Title: Interventions to help support caregivers of people with a brain or spinal cord tumour Title: Interventions
support caregivers
with a brain or spinal
mour
Patient or population: Adult caregivers of patients with a brain or spinal cord tumour
Settings: Any
Intervention: Any intervention aimed at improving caregiver well-being
Comparison: Any control condition (e.g. waiting list control groups; attention only control groups; information only control groups)
Patient or population:
caregivers of patients
brain or spinal cor
Settings: Any
Intervention: Any
aimed at improving
well-being
Comparison: Any
dition (e.g. waiting
groups; attention
groups; information
trol groups)
Outcomes Illustrative comparative risks* Relative effect
(95% CI)
No of partici-
pants
(studies)
Quality of evi-
dence
(GRADE)
Comment
Assumed risk Corresponding
risk
1. Caregiver psy-
chological
distress
2. Caregiver bur-
den
3. Caregiver
mastery
4. Quality of pa-
tient-caregiver
relationship
5. Caregiver
quality of life
6.
Caregiver physi-
cal functioning
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(Continued)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk
(and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; HR: hazard ratio; MD: mean difference; RR: risk ratio; OR: odds ratio
*The basis for the
(e.g. the median control
risk across studies)
in footnotes. The
ing risk (and its
dence interval) is
assumed risk in the
group and the relative
the intervention
CI).
CI: confidence inter
hazard ratio; MD:
ence; RR: risk ratio;
ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
GRADE Working
grades of evidence
High quality: Fur
is very unlikely to
confidence in the
effect.
Moderate quality:
search is likely to
portant impact on
dence in the estimate
and may change the
Low quality: Fur
is very likely to have
tant impact on our
in the estimate of
likely to change the
Very low quality:
uncertain about the
C O N T R I B U T I O N S O F A U T H O R S
FB drafted the protocol. The other review authors reviewed the protocol to improve its quality.
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D E C L A R A T I O N S O F I N T E R E S T
FB: involved in a RCT aimed at supporting informal caregivers of high-grade glioma patients through psycho-education and cognitive
behavioural therapy.
PS: involved in an ongoing trial to support family caregivers of patients diagnosed with a primary brain tumour through a nurse-guided
online programme.
HB: None known
CB: None known
AGR: None known
S O U R C E S O F S U P P O R T
Internal sources
• New Source of support, Other.
External sources
• No sources of support supplied
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